Acurx Pharmaceuticals Llc Stock Analysis
ACXP Stock | USD 1.25 0.10 8.70% |
Acurx Pharmaceuticals LLC is undervalued with Real Value of 3.99 and Target Price of 12.33. The main objective of Acurx Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Acurx Pharmaceuticals LLC is worth, separate from its market price. There are two main types of Acurx Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Acurx Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Acurx Pharmaceuticals is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Acurx Stock trading window is adjusted to America/New York timezone.
Acurx |
Acurx Stock Analysis Notes
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.09. Acurx Pharmaceuticals LLC had not issued any dividends in recent years. Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York. Acurx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. For more info on Acurx Pharmaceuticals LLC please contact the company at 917 533 1469 or go to https://www.acurxpharma.com.Acurx Pharmaceuticals LLC Investment Alerts
Acurx Pharmaceuticals generated a negative expected return over the last 90 days | |
Acurx Pharmaceuticals may become a speculative penny stock | |
Acurx Pharmaceuticals has high historical volatility and very poor performance | |
Acurx Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (14.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Acurx Pharmaceuticals LLC currently holds about 9.09 M in cash with (9.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8. | |
Acurx Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Roughly 15.0% of the company shares are held by company insiders | |
Latest headline from cnbc.com: Acurx Pharmaceuticals to add up to 1 million in bitcoin for treasury reserve, following MicroStrategys playbook |
Acurx Pharmaceuticals LLC Upcoming and Recent Events
21st of March 2024 Upcoming Quarterly Report | View | |
10th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Acurx Largest EPS Surprises
Earnings surprises can significantly impact Acurx Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-13 | 2024-09-30 | -0.2 | -0.17 | 0.03 | 15 | ||
2023-11-13 | 2023-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
2024-08-08 | 2024-06-30 | -0.22 | -0.26 | -0.04 | 18 |
Acurx Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Patriot Financial Group Insurance Agency, Llc | 2024-09-30 | 10.4 K | Tocqueville Asset Management L.p. | 2024-09-30 | 10 K | Semmax Financial Advisors Inc. | 2024-06-30 | 5.9 K | Group One Trading, Lp | 2024-06-30 | 5.2 K | Tower Research Capital Llc | 2024-06-30 | 4.1 K | Cornerstone Planning Group Llc | 2024-09-30 | 3.3 K | Simplex Trading, Llc | 2024-06-30 | 2.9 K | Northwestern Mutual Wealth Management Co | 2024-06-30 | 1.6 K | Ubs Group Ag | 2024-06-30 | 881 | Vanguard Group Inc | 2024-09-30 | 529.3 K | Prospect Financial Services Llc | 2024-09-30 | 295.1 K |
Acurx Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.34 M.Acurx Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.89) | (1.99) | |
Return On Capital Employed | (3.12) | (3.28) | |
Return On Assets | (1.89) | (1.99) | |
Return On Equity | (3.12) | (3.28) |
Management Efficiency
Acurx Pharmaceuticals LLC has return on total asset (ROA) of (1.3222) % which means that it has lost $1.3222 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4694) %, meaning that it created substantial loss on money invested by shareholders. Acurx Pharmaceuticals' management efficiency ratios could be used to measure how well Acurx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -1.99. In addition to that, Return On Capital Employed is likely to drop to -3.28. At this time, Acurx Pharmaceuticals' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/29/2024, Change To Liabilities is likely to grow to about 1.5 M, while Total Current Liabilities is likely to drop slightly above 1.8 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.37 | 0.42 | |
Tangible Book Value Per Share | 0.37 | 0.42 | |
Enterprise Value Over EBITDA | (2.53) | (2.65) | |
Price Book Value Ratio | 10.40 | 9.88 | |
Enterprise Value Multiple | (2.53) | (2.65) | |
Price Fair Value | 10.40 | 9.88 | |
Enterprise Value | 41.1 M | 56.6 M |
The management strategies employed by Acurx Pharmaceuticals' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta (1.72) | Return On Assets (1.32) | Return On Equity (3.47) |
Technical Drivers
As of the 29th of November, Acurx Pharmaceuticals shows the Standard Deviation of 3.75, risk adjusted performance of (0.17), and Mean Deviation of 2.21. Acurx Pharmaceuticals LLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Acurx Pharmaceuticals LLC Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Acurx Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Acurx Pharmaceuticals LLC. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Acurx Pharmaceuticals LLC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acurx Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acurx Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acurx Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Acurx Pharmaceuticals Outstanding Bonds
Acurx Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Acurx Pharmaceuticals LLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Acurx bonds can be classified according to their maturity, which is the date when Acurx Pharmaceuticals LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
ACURIS FIN 5 Corp BondUS00511BAA52 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 4875 Corp BondUS55336VAG59 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View |
Acurx Pharmaceuticals Predictive Daily Indicators
Acurx Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Acurx Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Acurx Pharmaceuticals Forecast Models
Acurx Pharmaceuticals' time-series forecasting models are one of many Acurx Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acurx Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Acurx Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Acurx Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acurx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Acurx Pharmaceuticals. By using and applying Acurx Stock analysis, traders can create a robust methodology for identifying Acurx entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Acurx Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acurx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acurx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
12.33 | Buy | 2 | Odds |
Most Acurx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acurx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acurx Pharmaceuticals LLC, talking to its executives and customers, or listening to Acurx conference calls.
Acurx Stock Analysis Indicators
Acurx Pharmaceuticals LLC stock analysis indicators help investors evaluate how Acurx Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acurx Pharmaceuticals shares will generate the highest return on investment. By understating and applying Acurx Pharmaceuticals stock analysis, traders can identify Acurx Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 9.1 M | |
Common Stock Shares Outstanding | 12.7 M | |
Total Stockholder Equity | 4.7 M | |
Cash And Short Term Investments | 7.5 M | |
Cash | 7.5 M | |
Accounts Payable | 3809.00 | |
Net Debt | -7.5 M | |
50 Day M A | 1.8684 | |
Total Current Liabilities | 3 M | |
Other Operating Expenses | 14.6 M | |
Stock Based Compensation | 3.8 M |
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.